Why compare them?
These records are compared to clarify how their mechanisms, research areas, and evidence maturity differ.
Simple first. Deeper when you want it.
Understand the differences that matter.
See the biggest similarities, differences, strengths, limitations, and unanswered questions first—then open the evidence behind them.
Compound comparison
CJC-1295 vs. Tirzepatide
Understand the meaningful overlap, differences, evidence, and unknowns—then go deeper only when you want to.
60-Second Summary
The answer first
Current evidenceComparable evidence base
No direct head-to-head study is represented. This comparison uses separate evidence records that may differ in population, duration, route, dose, and endpoint.
✓ Shared
Shared Similarities
- Both have controlled human research, although the questions and designs may differ.
⇄ Different
Biggest Difference
CJC-1295 is distinguished by gHRH-receptor agonist family. The published human pharmacology appears to involve the long-acting DAC active moiety; non-DAC/Mod GRF forms are not interchangeable; Tirzepatide is distinguished by dual agonist at GIP and GLP-1 receptors, with approved U.S. products and a much larger completed evidence base.
? Unknown
Biggest Unknown
No direct head-to-head study establishes how these compounds compare under the same population, dose, duration, and endpoints.
Key Takeaways
CJC-1295 is distinguished in the current record by gHRH-receptor agonist family. The published human pharmacology appears to involve the long-acting DAC active moiety; non-DAC/Mod GRF forms are not interchangeable. Tirzepatide is distinguished by dual agonist at GIP and GLP-1 receptors, with approved U.S. products and a much larger completed evidence base. Neither is objectively “better”; the useful question is which evidence record addresses the research question being asked.
Research matrix
Which question has stronger current support?
Research questionStronger current supportExplanation
Human evidenceTirzepatide
CJC-1295: Early human pharmacology. Tirzepatide: Mature human evidence.
Regulatory historyTirzepatide
CJC-1295: Not approved. Tirzepatide: FDA approved for defined indications.
Mechanistic breadthTirzepatide
More named targets describes mechanistic breadth; it does not establish greater effectiveness.
Direct comparisonUnknown
Separate studies cannot establish comparative superiority.
Deeper when you want it
Explore the evidence and nuance
Best-studied areas and pathway mapSee shared targets, unique pathways, and the research questions attached to each record.
CJC-1295
- Growth hormone and IGF-1 pharmacology
- Hormone pulsatility
- HIV-associated visceral obesity — terminated trial
Tirzepatide
- Obesity
- Type 2 diabetes
- Cardiometabolic outcomes
Pathway and research map
Shared foundation and unique questions
Research confidence by questionCompare regulatory, human-evidence, outcome, and administration records side by side.
Question by question
What each evidence base can actually answer
Regulatory statusEvidence, not a winner
CJC-1295Not approved
Not FDA approved. FDA distinguishes five CJC-1295-related bulk substances across two active moieties; the 2024 PCAC voted against 503A Bulks List inclusion for the evaluated forms.
TirzepatideFDA-labeled indications
FDA approved as Mounjaro for type 2 diabetes and Zepbound for defined adult weight-management and OSA indications.
Evidence depthEvidence, not a winner
CJC-1295Small PK/PD studies
Two small controlled human PK/PD studies, a small pulsatility analysis, and a terminated Phase 2 registration without posted results.
TirzepatideMature Phase 3
Multiple large Phase 3 trials, active-comparator studies, 176-week follow-up, a 13,299-participant cardiovascular outcomes trial, and newer 2026 maintenance data.
Weight outcomesEvidence, not a winner
CJC-1295No completed outcome trial
No completed controlled human weight- or body-composition outcome study was located. A visceral-obesity trial was terminated without posted results.
TirzepatidePeer-reviewed Phase 3
SURMOUNT-1 peer-reviewed trial: mean change −15.0%, −19.5%, and −20.9% across studied doses versus −3.1% placebo at 72 weeks.
Type 2 diabetesEvidence, not a winner
CJC-1295No dedicated evidence
No dedicated controlled human diabetes-outcome study was located.
TirzepatideApproved + Phase 3
Extensive SURPASS program and FDA approval. SURPASS-2 directly compared tirzepatide with semaglutide 1 mg in type 2 diabetes.
Obstructive sleep apnoeaEvidence, not a winner
CJC-1295No dedicated evidence
No dedicated controlled human obstructive-sleep-apnoea outcome study was located.
TirzepatideApproved + Phase 3
Two peer-reviewed Phase 3 trials support the FDA-approved Zepbound indication for moderate-to-severe OSA in adults with obesity.
Cardiovascular outcomesEvidence, not a winner
CJC-1295Long-term unknown
Long-term cardiovascular safety is unresolved. A Phase 2 participant died after myocardial infarction; the attending physician attributed the event to underlying coronary disease, and the trial published no results.
TirzepatideCVOT + HFpEF trial
SURPASS-CVOT found tirzepatide noninferior—but not superior—to dulaglutide for major cardiovascular events. In SUMMIT, a separate placebo-controlled HFpEF-and-obesity population had fewer composite cardiovascular-death or worsening-heart-failure events; that finding is population-specific.
Administration and handlingEvidence, not a winner
CJC-1295DAC research arms only
Human pharmacology used protocol-defined subcutaneous CJC-1295 DAC. This does not establish an approved dose, route, schedule, or handling process for DAC, non-DAC, or named salt products.
TirzepatideOfficial FDA label
FDA labels provide product-specific once-weekly subcutaneous dosing and handling. Approved presentations are solutions; no reconstitution is required.
Comparison limitationsUnderstand what this comparison cannot establish before interpreting separate studies.
Comparable evidence base
- No direct head-to-head trial is represented for this pair.
- Separate studies may use different populations, endpoints, durations, doses, routes, and estimands.
- Results should not be interpreted as comparative superiority or individual guidance.
Current unknowns
Questions the evidence cannot answer yet
- Clinical outcomes, long-term safety, product identity, and whether any findings apply to non-DAC/Mod GRF(1-29).
- Long-term individual durability and rare events, plus evidence for uses outside studied and approved populations.
Community Intelligence
Emerging patterns, clearly separated from evidence
CJC-1295
No community experiences yetBe the first account holder to contribute.
Tirzepatide
No community experiences yetBe the first account holder to contribute.
Community Intelligence summarizes structured, self-reported experiences. It can reveal patterns and useful research questions, but it cannot prove safety, effectiveness, or cause and effect. Published evidence is always shown separately.